Search

Your search keyword '"Ritterhouse, Lauren L."' showing total 319 results
Start Over Author "Ritterhouse, Lauren L."
319 results on '"Ritterhouse, Lauren L."'

1. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Author

Singh, Harshabad, Lowder, Kristen E., Kapner, Kevin, Kelly, Ronan J., Zheng, Hui, McCleary, Nadine Jackson, Abrams, Thomas A., Chan, Jennifer A., Regan, Eileen M., Klempner, Samuel J., Hannigan, Alison M., Remland, Joshua, Brais, Lauren K., Andrews, Elizabeth, Yurgelun, Matthew, Cleary, James M., Rubinson, Douglas A., Ritterhouse, Lauren L., Maron, Garrett, Aguirre, Andrew J., Meyerhardt, Jeffrey A., Gardecki, Emma, Lennerz, Jochen K., Wolpin, Brian M., and Enzinger, Peter C.

Published
2024
Full Text
View/download PDF

3. Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Author

Sirohi, Deepika, Schmidt, Robert L, Aisner, Dara L, Behdad, Amir, Betz, Bryan L, Brown, Noah, Coleman, Joshua F, Corless, Christopher L, Deftereos, Georgios, Ewalt, Mark D, Fernandes, Helen, Hsiao, Susan J, Mansukhani, Mahesh M, Murray, Sarah S, Niu, Nifang, Ritterhouse, Lauren L, Suarez, Carlos J, Tafe, Laura J, Thorson, John A, Segal, Jeremy P, and Furtado, Larissa V

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Good Health and Well Being, Genetic Association Studies, Genetic Predisposition to Disease, Genetic Testing, Genetic Variation, Humans, Neoplasms, Practice Guidelines as Topic, Reproducibility of Results, Sensitivity and Specificity, United States, Medical Microbiology, Pathology, Clinical sciences, Oncology and carcinogenesis
Abstract

This multi-institutional study was undertaken to evaluate interrater reliability of the 2017 Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists guidelines for interpretation and reporting of oncology sequence variants and to assess current practices and perceptions surrounding these guidelines. Fifty-one variants were distributed to 20 participants from 10 institutions for classification using the new guidelines. Agreement was assessed using chance-corrected agreement (Cohen κ). κ was 0.35. To evaluate if data sharing could help resolve disagreements, a summary of variant classifications and additional information about each variant were distributed to all participants. κ improved to 0.7 after the original classifications were revised. Participants were invited to take a web-based survey regarding their perceptions of the guidelines. Only 20% (n = 3) of the survey respondents had prior experience with the guidelines in clinical practice. The main perceived barriers to guideline implementation included the complexity of the guidelines, discordance between clinical actionability and pathobiologic relevance, lack of familiarity with the new classifications, and uncertainty when applying criteria to potential germline variants. This study demonstrates noteworthy discordances between pathologists for variant classification in solid tumors when using the 2017 Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists guidelines. These findings highlight potential areas for clarification/refinement before mainstream clinical adoption.

Published
2020

8. Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma

Author

Gupta, Mihir, primary, Bradley, Joseph, additional, Massaad, Elie, additional, Burns, Evan, additional, Georgantas, N. Zeke, additional, Maron, Garrett, additional, Batten, Julie, additional, Gallagher, Aidan, additional, Thierauf, Julia, additional, Nayyar, Naema, additional, Gordon, Amanda, additional, Jones, SooAe, additional, Pisapia, Michelle, additional, Sun, Ying, additional, Jones, Pamela Stuart, additional, Barker, Fred G., additional, Curry, William, additional, Gupta, Rajiv, additional, Romero, Javier, additional, Wang, Nancy, additional, Brastianos, Priscilla, additional, Martinez-Lage, Maria, additional, Tateishi, Kensuke, additional, Forst, Deborah Anne, additional, Nahed, Brian Vala, additional, Batchelor, Tracy T, additional, Ritterhouse, Lauren L, additional, Iser, Florian, additional, Kessler, Tobias, additional, Jordan, Justin T., additional, Dietrich, Jorg, additional, Meyerson, Matthew L., additional, Cahill, Daniel P., additional, Lennerz, Jochen K, additional, Carter, Bob, additional, and Shankar, Ganesh M., additional

Published
2024
Full Text
View/download PDF

12. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.

Author

Mata, Douglas A, Lee, Jessica K, Shanmugam, Vignesh, Marcus, Chelsea B, Schrock, Alexa B, Williams, Erik A, Ritterhouse, Lauren L, Hickman, Richard A, Janovitz, Tyler, Patel, Nimesh R, Kroger, Benjamin R, Ross, Jeffrey S, Mirza, Kamran M, Oxnard, Geoffrey R, Vergilio, Jo‐Anne, Elvin, Julia A, Benhamida, Jamal K, Decker, Brennan, and Xu, Mina L

Subjects
CIRCULATING tumor DNA, DNA analysis, DIFFUSE large B-cell lymphomas, SPECTRUM analysis, ACUTE myeloid leukemia, MYELOPROLIFERATIVE neoplasms
Abstract

Aims: Liquid biopsy (LBx)‐based next‐generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue‐based NGS is infeasible. Methods and Results: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non‐Hodgkin lymphoma (NHL), 43 plasma‐cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B‐cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML). Among 73.4% with detectable pathogenic alterations, median maximum somatic allele frequency (MSAF) was 16.6%, with AML (36.2%), MDS (19.7%), and MPN (44.5%) having higher MSAFs than DLBCL (3.9%), NHL (8.4%), HL (1.5%), PCN (2.8%), and histiocytoses (1.8%) (P = 0.001). LBx detected characteristic alterations across HNs, including in TP53, KRAS, MYD88, and BTK in NHLs; TP53, KRAS, NRAS, and BRAF in PCNs; IGH in DLBCL; TP53, ATM, and PDCD1LG2 in HL; BRAF and MAP2K1 in histiocytoses; TP53, SF3B1, DNMT3A, TET2, and ASXL1 in MDS; JAK2 in MPNs; and FLT3, IDH2, and NPM1 in AML. Among 24 samples, the positive percent agreement by LBx was 75.7% for variants present in paired buffy coat, marrow, or tissues. Also, 75.0% of pairs exhibited alterations only present on LBx. These were predominantly subclonal (clonal fraction of 3.8%), reflecting the analytical sensitivity of LBx. Conclusion: These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy‐resistant clones that may be undetectable in site‐specific tissue biopsies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data

Author

Scott, Jeffrey A., primary, Lennerz, Jochen, additional, Johnson, Melissa Lynne, additional, Gordan, Lucio N., additional, Dumanois, Robert H., additional, Quagliata, Luca, additional, Ritterhouse, Lauren L., additional, Cappuzzo, Federico, additional, Wang, Brandon, additional, Xue, Mei, additional, Vasudevan, Anupama, additional, Varughese, Prateesh, additional, Vaidya, Varun, additional, Gart, Mike, additional, Dorrow, Natalie, additional, Gierman, Hinco J., additional, and Choksi, Rushir J., additional

Published
2023
Full Text
View/download PDF

23. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.

Author

Scott, Jeffrey A., Lennerz, Jochen, Johnson, Melissa Lynne, Gordan, Lucio N., Dumanois, Robert H., Quagliata, Luca, Ritterhouse, Lauren L., Cappuzzo, Federico, Wang, Brandon, Mei Xue, Vasudevan, Anupama, Varughese, Prateesh, Vaidya, Varun, Gart, Mike, Dorrow, Natalie, Gierman, Hinco J., and Choksi, Rushir J.

Subjects
PROTEIN analysis, LUNG cancer, GENETIC mutation, SCIENTIFIC observation, CONFIDENCE intervals, RETROSPECTIVE studies, REGRESSION analysis, TUMOR classification, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness, COMPARATIVE studies, GENOMICS, KAPLAN-Meier estimator, DESCRIPTIVE statistics, DATA analysis software, OVERALL survival
Abstract

Purpose Identification and targeting of actionable oncogenic drivers (AODs) in advanced non–small-cell lung cancer (NSCLC) has dramatically improved outcomes. However, genomic testing uptake is variable and hampered by factors including slow turnaround time, frequently resulting in initial non–tyrosine kinase inhibitor (TKI) treatment. We investigate how this behavior affects outcomes. Methods This retrospective analysis of real-world, deidentified data from the Integra Connect Database included adults with stage IV NSCLC newly diagnosed from January 1, 2018, to December 31, 2020, with mutations of EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2, or NTRK. Outcomes were reported as time to next treatment or death (TTNT) and overall survival (OS). Results Five hundred ten patients harboring AODs were identified and grouped as follows: group A (n = 379) were treated after the AOD was reported and served as the comparator. One hundred thirty-one patients treated before their AOD report were divided into group B (n = 47) who were initially started on chemotherapy and/or checkpoint inhibitor but switched to appropriate TKI within 35 days and group C (n = 84) who were also started empirically on non-TKI and did not switch within 35 days. Survival (OS) was significantly superior in group A compared with group C; TTNT was significantly superior in group A compared with groups B and C. Conclusion For patients harboring AODs in advanced NSCLC, initial treatment before receipt of genomic test results yields significantly inferior outcomes and should be avoided. Molecular profiling panels with rapid turnaround times are essential to optimize patient outcomes and should be standard of care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Abstract CT155: Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

Author

Singh, Harshabad, primary, Lowder, Kristen E., additional, Kapner, Kevin, additional, Kelly, Ronan J., additional, Zheng, Hui, additional, McCleary, Nadine J., additional, Abrams, Thomas A., additional, Chan, Jennifer A., additional, Regan, Eileen M., additional, Klempner, Samuel J., additional, Hannigan, Alison M., additional, Brais, Lauren K., additional, Andrews, Elizabeth A., additional, Yurgelun, Matthew B., additional, Cleary, James M., additional, Rubinson, Douglas A., additional, Ritterhouse, Lauren L., additional, Maron, Garrett E., additional, Aguirre, Andrew J., additional, Tan, Lu, additional, Du, Pan, additional, Meyerhardt, Jeffrey A., additional, Gardecki, Emma, additional, Lennerz, Jochen K., additional, Jia, Shidong, additional, Wolpin, Brian M., additional, and Enzinger, Peter C., additional

Published
2023
Full Text
View/download PDF

28. Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Author

Rudzinski, Erin R., primary, Ladanyi, Marc, additional, Ritterhouse, Lauren L., additional, Sahm, Felix, additional, Norenberg, Ricarda, additional, Zheng, Hong, additional, Chen, Chi, additional, Bernard-Gauthier, Vadim, additional, Brega, Nicoletta, additional, van Tilburg, Cornelis M., additional, Lin, Jessica J., additional, Brose, Marcia S., additional, Lassen, Ulrik N., additional, McDermott, Ray, additional, Laetsch, Theodore W., additional, Hong, David S., additional, Drilon, Alexander, additional, and Roy-Chowdhuri, Sinchita, additional

Published
2023
Full Text
View/download PDF

29. Data from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Author

Gainor, Justin F., primary, Dardaei, Leila, primary, Yoda, Satoshi, primary, Friboulet, Luc, primary, Leshchiner, Ignaty, primary, Katayama, Ryohei, primary, Dagogo-Jack, Ibiayi, primary, Gadgeel, Shirish, primary, Schultz, Katherine, primary, Singh, Manrose, primary, Chin, Emily, primary, Parks, Melissa, primary, Lee, Dana, primary, DiCecca, Richard H., primary, Lockerman, Elizabeth, primary, Huynh, Tiffany, primary, Logan, Jennifer, primary, Ritterhouse, Lauren L., primary, Le, Long P., primary, Muniappan, Ashok, primary, Digumarthy, Subba, primary, Channick, Colleen, primary, Keyes, Colleen, primary, Getz, Gad, primary, Dias-Santagata, Dora, primary, Heist, Rebecca S., primary, Lennerz, Jochen, primary, Sequist, Lecia V., primary, Benes, Cyril H., primary, Iafrate, A. John, primary, Mino-Kenudson, Mari, primary, Engelman, Jeffrey A., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Tables S1 - S14 from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Author

Gainor, Justin F., primary, Dardaei, Leila, primary, Yoda, Satoshi, primary, Friboulet, Luc, primary, Leshchiner, Ignaty, primary, Katayama, Ryohei, primary, Dagogo-Jack, Ibiayi, primary, Gadgeel, Shirish, primary, Schultz, Katherine, primary, Singh, Manrose, primary, Chin, Emily, primary, Parks, Melissa, primary, Lee, Dana, primary, DiCecca, Richard H., primary, Lockerman, Elizabeth, primary, Huynh, Tiffany, primary, Logan, Jennifer, primary, Ritterhouse, Lauren L., primary, Le, Long P., primary, Muniappan, Ashok, primary, Digumarthy, Subba, primary, Channick, Colleen, primary, Keyes, Colleen, primary, Getz, Gad, primary, Dias-Santagata, Dora, primary, Heist, Rebecca S., primary, Lennerz, Jochen, primary, Sequist, Lecia V., primary, Benes, Cyril H., primary, Iafrate, A. John, primary, Mino-Kenudson, Mari, primary, Engelman, Jeffrey A., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figures S1 - S9 from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Author

Gainor, Justin F., primary, Dardaei, Leila, primary, Yoda, Satoshi, primary, Friboulet, Luc, primary, Leshchiner, Ignaty, primary, Katayama, Ryohei, primary, Dagogo-Jack, Ibiayi, primary, Gadgeel, Shirish, primary, Schultz, Katherine, primary, Singh, Manrose, primary, Chin, Emily, primary, Parks, Melissa, primary, Lee, Dana, primary, DiCecca, Richard H., primary, Lockerman, Elizabeth, primary, Huynh, Tiffany, primary, Logan, Jennifer, primary, Ritterhouse, Lauren L., primary, Le, Long P., primary, Muniappan, Ashok, primary, Digumarthy, Subba, primary, Channick, Colleen, primary, Keyes, Colleen, primary, Getz, Gad, primary, Dias-Santagata, Dora, primary, Heist, Rebecca S., primary, Lennerz, Jochen, primary, Sequist, Lecia V., primary, Benes, Cyril H., primary, Iafrate, A. John, primary, Mino-Kenudson, Mari, primary, Engelman, Jeffrey A., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

Author

de Jonge, Marthe M., primary, Ritterhouse, Lauren L., primary, de Kroon, Cornelis D., primary, Vreeswijk, Maaike P.G., primary, Segal, Jeremy P., primary, Puranik, Rutika, primary, Hollema, Harry, primary, Rookus, Matti A., primary, van Asperen, Christi J., primary, van Leeuwen, Flora E., primary, Smit, Vincent T.H.B.M., primary, Howitt, Brooke E., primary, and Bosse, Tjalling, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Fig. S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

Author

de Jonge, Marthe M., primary, Ritterhouse, Lauren L., primary, de Kroon, Cornelis D., primary, Vreeswijk, Maaike P.G., primary, Segal, Jeremy P., primary, Puranik, Rutika, primary, Hollema, Harry, primary, Rookus, Matti A., primary, van Asperen, Christi J., primary, van Leeuwen, Flora E., primary, Smit, Vincent T.H.B.M., primary, Howitt, Brooke E., primary, and Bosse, Tjalling, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Material and Methods from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

Author

de Jonge, Marthe M., primary, Ritterhouse, Lauren L., primary, de Kroon, Cornelis D., primary, Vreeswijk, Maaike P.G., primary, Segal, Jeremy P., primary, Puranik, Rutika, primary, Hollema, Harry, primary, Rookus, Matti A., primary, van Asperen, Christi J., primary, van Leeuwen, Flora E., primary, Smit, Vincent T.H.B.M., primary, Howitt, Brooke E., primary, and Bosse, Tjalling, primary

Published
2023
Full Text
View/download PDF

40. Diagnostic quality model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML

Author

Lennerz, Jochen K., primary, Salgado, Roberto, additional, Kim, Grace E., additional, Sirintrapun, Sahussapont Joseph, additional, Thierauf, Julia C., additional, Singh, Ankit, additional, Indave, Iciar, additional, Bard, Adam, additional, Weissinger, Stephanie E., additional, Heher, Yael K., additional, de Baca, Monica E., additional, Cree, Ian A., additional, Bennett, Shannon, additional, Carobene, Anna, additional, Ozben, Tomris, additional, and Ritterhouse, Lauren L., additional

Published
2023
Full Text
View/download PDF

41. Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series

Author

Brett, Jamie O, primary, Ritterhouse, Lauren L, additional, Newman, Erik T, additional, Irwin, Kelly E, additional, Dawson, Megan, additional, Ryan, Lianne Y, additional, Spring, Laura M, additional, Rivera, Miguel N, additional, Lennerz, Jochen K, additional, Dias-Santagata, Dora, additional, Ellisen, Leif W, additional, Bardia, Aditya, additional, and Wander, Seth A, additional

Published
2022
Full Text
View/download PDF

45. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

Author

Dias-Santagata, Dora, primary, Heist, Rebecca S, additional, Bard, Adam Z, additional, da Silva, Annacarolina F L, additional, Dagogo-Jack, Ibiayi, additional, Nardi, Valentina, additional, Ritterhouse, Lauren L, additional, Spring, Laura M, additional, Jessop, Nicholas, additional, Farahani, Alexander A, additional, Mino-Kenudson, Mari, additional, Allen, Jill, additional, Goyal, Lipika, additional, Parikh, Aparna, additional, Misdraji, Joseph, additional, Shankar, Ganesh, additional, Jordan, Justin T, additional, Martinez-Lage, Maria, additional, Frosch, Matthew, additional, Graubert, Timothy, additional, Fathi, Amir T, additional, Hobbs, Gabriela S, additional, Hasserjian, Robert P, additional, Raje, Noopur, additional, Abramson, Jeremy, additional, Schwartz, Joel H, additional, Sullivan, Ryan J, additional, Miller, David, additional, Hoang, Mai P, additional, Isakoff, Steven, additional, Ly, Amy, additional, Bouberhan, Sara, additional, Watkins, Jaclyn, additional, Oliva, Esther, additional, Wirth, Lori, additional, Sadow, Peter M, additional, Faquin, William, additional, Cote, Gregory M, additional, Hung, Yin P, additional, Gao, Xin, additional, Wu, Chin-Lee, additional, Garg, Salil, additional, Rivera, Miguel, additional, Le, Long P, additional, John Iafrate, A, additional, Juric, Dejan, additional, Hochberg, Ephraim P, additional, Clark, Jeffrey, additional, Bardia, Aditya, additional, and Lennerz, Jochen K, additional

Published
2022
Full Text
View/download PDF

46. Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions

Author

Brett, Jamie O., primary, Weipert, Caroline M., additional, Ritterhouse, Lauren L., additional, Zhang, Nicole, additional, Yu, Junhua, additional, Ryan, Lianne Y., additional, Spring, Laura M., additional, Rivera, Miguel N., additional, Lennerz, Jochen K., additional, Dias-Santagata, Dora, additional, Ellisen, Leif W., additional, Bardia, Aditya, additional, and Wander, Seth A., additional

Published
2022
Full Text
View/download PDF

47. Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma

Author

Thierauf, Julia C., primary, Farahani, Alex A., additional, Indave, B. Iciar, additional, Bard, Adam Z., additional, White, Valerie A., additional, Smith, Cameron R., additional, Marble, Hetal, additional, Hyrcza, Martin D., additional, Chan, John K. C., additional, Bishop, Justin, additional, Shi, Qiuying, additional, Ely, Kim, additional, Agaimy, Abbas, additional, Martinez-Lage, Maria, additional, Nose, Vania, additional, Rivera, Miguel, additional, Nardi, Valentina, additional, Dias-Santagata, Dora, additional, Garg, Salil, additional, Sadow, Peter, additional, Le, Long P., additional, Faquin, William, additional, Ritterhouse, Lauren L., additional, Cree, Ian A., additional, Iafrate, A. John, additional, and Lennerz, Jochen K., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results